DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vivelle (Estradiol Transdermal) - Dysarthria - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Dysarthria (8)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vivelle (Estradiol Transdermal) where reactions include dysarthria. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Vivelle side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-15

Patient: female, weighing 89.4 kg (196.7 pounds)

Reactions: Dysarthria, Polymedication, Mental Status Changes, Headache, Hypertension, Asthenia, Hypokalaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Lexapro
    Administration route: Oral
    Indication: Post-Traumatic Stress Disorder

Ambien
    Administration route: Oral
    Indication: Insomnia

Lyrica
    Administration route: Oral
    Indication: Fibromyalgia

Clonazepam
    Administration route: Oral
    Indication: Bipolar Disorder

Ibuprofen
    Administration route: Oral
    Indication: Fibromyalgia

Placebo
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Lexapro
    Administration route: Oral
    Indication: Bipolar Disorder

Robaxin
    Indication: Fibromyalgia

Zestoretic
    Dosage: 20/12.5 daily
    Administration route: Oral
    Indication: Hypertension
    Start date: 2008-12-04

Desvenlafaxine Succinate Monohydrate
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Placebo
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Loratadine
    Administration route: Oral
    Indication: Seasonal Allergy

Vicodin
    Dosage: 5/500 as needed
    Administration route: Oral
    Indication: Fibromyalgia

Vivelle
    Indication: Hormone Replacement Therapy

Desvenlafaxine Succinate Monohydrate
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Abilify
    Administration route: Oral
    Indication: Bipolar I Disorder

Fluticasone
    Indication: Seasonal Allergy



Possible Vivelle side effects in female

Reported by a physician from United States on 2012-03-13

Patient: female, weighing 89.4 kg (196.7 pounds)

Reactions: Dysarthria, Polymedication, Mental Status Changes, Condition Aggravated, Hypertension, Hypokalaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Abilify
    Dosage: 15 mg, 2x/day
    Administration route: Oral
    Indication: Bipolar I Disorder

Blinded Desvenlafaxine Succinate Monohydrate
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Lexapro
    Dosage: 20 mg, 1x/day
    Administration route: Oral
    Indication: Post-Traumatic Stress Disorder

Fluticasone
    Dosage: 2 sprays daily route: in
    Indication: Seasonal Allergy

Blinded Placebo
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Lyrica
    Dosage: 75 mg, 1x/day
    Administration route: Oral
    Indication: Fibromyalgia

Robaxin
    Dosage: 750 mg, 3x/day
    Administration route: Oral
    Indication: Fibromyalgia

Clonazepam
    Dosage: 1 mg, 2x/day
    Administration route: Oral
    Indication: Bipolar Disorder

Vicodin
    Dosage: 5/500 prn
    Administration route: Oral
    Indication: Fibromyalgia

Blinded Placebo
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Loratadine
    Dosage: 10 mg, 1x/day
    Administration route: Oral
    Indication: Seasonal Allergy

Robaxin
    Dosage: unknown

Lexapro
    Indication: Bipolar Disorder

Vivelle
    Dosage: 0.1 mg, unk
    Indication: Hormone Replacement Therapy

Ibuprofen
    Dosage: 800 mg, 3x/day
    Administration route: Oral
    Indication: Fibromyalgia

Ambien
    Dosage: 10 mg, 1x/day
    Administration route: Oral
    Indication: Insomnia

Blinded Desvenlafaxine Succinate Monohydrate
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Blinded NO Subject Drug
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Zestoretic
    Dosage: 20/12.5 daily
    Administration route: Oral
    Indication: Hypertension
    Start date: 2008-12-04

Blinded NO Subject Drug
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24



Possible Vivelle side effects in female

Reported by a physician from United States on 2012-02-10

Patient: female

Reactions: Thrombosis, Asthma, Lymphadenopathy, Hypoglycaemia, Osteomyelitis, Lipids Increased, Cerebrovascular Disorder, Peripheral Sensory Neuropathy, Oedema Peripheral, Uterine Leiomyoma, Irritable Bowel Syndrome, Postmenopausal Haemorrhage, Hypoxia, Breast Cancer, Pneumonia, Pain in Extremity, Mastitis, Breast Mass, Hypoaesthesia, Diverticulum Intestinal, Adenomyosis, Diabetic Neuropathy, Staphylococcal Infection, Nervous System Disorder, Gastric Polyps, non-Hodgkin's Lymphoma, Sleep Apnoea Syndrome, Uterine Haemorrhage, Aphasia, Viith Nerve Paralysis, Fibrocystic Breast Disease, Neuropathy Peripheral, Fibromyalgia, Obesity, Depression, Lymphoedema, Transient Ischaemic Attack, Migraine, Abdominal Pain Lower, Type 2 Diabetes Mellitus, Motor Dysfunction, Urinary Tract Infection, Cognitive Disorder, Cystitis, Amnesia, Cerebrovascular Accident, Anxiety, Osteoarthritis, Dysarthria, Diarrhoea, Arthralgia, Dysuria, Flank Pain, Alopecia, Gait Disturbance, Hypertension

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Estraderm
    Dosage: 0.5 mg, unk
    Indication: Hormone Replacement Therapy
    Start date: 1994-04-01
    End date: 1997-06-01

Vivelle
    Dosage: 0.1 mg, unk
    Indication: Hormone Replacement Therapy
    Start date: 1997-10-01
    End date: 1997-12-01

Provera
    Dosage: 2.5 mg, unk
    Administration route: Oral
    Indication: Hormone Replacement Therapy
    Start date: 1994-03-01
    End date: 1994-08-01

Premarin
    Indication: Hormone Replacement Therapy

Medroxyprogesterone Acetate
    Dosage: 2.5 mg, unk
    Administration route: Oral
    Indication: Hormone Replacement Therapy
    Start date: 1994-09-01
    End date: 2000-02-16

Estraderm
    Dosage: 0.1 mg, unk
    Start date: 1997-08-01
    End date: 2000-02-01



Possible Vivelle side effects in female

Reported by a lawyer from United States on 2012-01-12

Patient: female

Reactions: Asthma, Thrombosis, Lymphadenopathy, Hypoglycaemia, Cerebrovascular Disorder, Lipids Increased, Peripheral Sensory Neuropathy, Uterine Leiomyoma, Irritable Bowel Syndrome, Hypoxia, Postmenopausal Haemorrhage, Breast Cancer, Pneumonia, Pain in Extremity, Breast Mass, Hypoaesthesia, Diverticulum Intestinal, Adenomyosis, Staphylococcal Infection, Diabetic Neuropathy, Nervous System Disorder, Gastric Polyps, non-Hodgkin's Lymphoma, Sleep Apnoea Syndrome, Uterine Haemorrhage, Aphasia, Viith Nerve Paralysis, Neuropathy Peripheral, Fibrocystic Breast Disease, Fibromyalgia, Obesity, Depression, Lymphoedema, Transient Ischaemic Attack, Migraine, Abdominal Pain Lower, Type 2 Diabetes Mellitus, Motor Dysfunction, Cognitive Disorder, Amnesia, Cerebrovascular Accident, Osteoarthritis, Dysarthria, Anxiety, Arthralgia, Diarrhoea, Gait Disturbance, Hypertension

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Estraderm
    Dosage: 0.5 mg, unk
    Indication: Hormone Replacement Therapy
    Start date: 1994-04-01
    End date: 1997-06-01

Vivelle
    Dosage: 0.1 mg, unk
    Indication: Hormone Replacement Therapy
    Start date: 1997-10-01
    End date: 1997-12-01

Premarin
    Indication: Hormone Replacement Therapy

Provera
    Dosage: 2.5 mg, unk
    Administration route: Oral
    Indication: Hormone Replacement Therapy
    Start date: 1994-03-01
    End date: 1994-08-01

Estraderm
    Dosage: 0.1 mg, unk
    Start date: 1997-08-01
    End date: 2000-02-01

Medroxyprogesterone Acetate
    Dosage: 2.5 mg, unk
    Administration route: Oral
    Indication: Hormone Replacement Therapy
    Start date: 1994-09-01
    End date: 2000-02-16



Possible Vivelle side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2011-12-23

Patient: female, weighing 89.4 kg (196.7 pounds)

Reactions: Dysarthria, Polymedication, Mental Status Changes, Headache, Hypertension, Asthenia, Hypokalaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Desvenlafaxine Succinate Monohydrate
    Administration route: Oral
    Start date: 2008-09-09
    End date: 2008-11-22

Lexapro
    Indication: Ill-Defined Disorder

Fluticasone Furoate
    Indication: Ill-Defined Disorder

Loratadine
    Indication: Ill-Defined Disorder

Vicodin
    Dosage: 5/500 as needed
    Indication: Ill-Defined Disorder

Ambien
    Administration route: Oral
    Indication: Ill-Defined Disorder

Lyrica
    Indication: Ill-Defined Disorder

Placebo
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Abilify
    Indication: Ill-Defined Disorder

Vivelle
    Indication: Ill-Defined Disorder

Zestoretic
    Dosage: 20/12.5 daily
    Indication: Ill-Defined Disorder

Desvenlafaxine Succinate Monohydrate
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-11-29
    End date: 2008-12-24

Robaxin
    Indication: Ill-Defined Disorder

Ibuprofen
    Indication: Ill-Defined Disorder

Placebo
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Clonazepam
    Indication: Ill-Defined Disorder



Possible Vivelle side effects in female

Reported by a physician from United States on 2011-12-20

Patient: female, weighing 89.4 kg (196.7 pounds)

Reactions: Dysarthria, Polymedication, Mental Status Changes, Condition Aggravated, Hypertension, Hypokalaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded Desvenlafaxine Succinate Monohydrate
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Blinded NO Subject Drug
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Blinded Desvenlafaxine Succinate Monohydrate
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Ibuprofen
    Dosage: 800 mg, 3x/day

Robaxin
    Dosage: unknown

Blinded Placebo
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Clonazepam
    Dosage: 1 mg, 2x/day

Lexapro
    Dosage: 20 mg, 1x/day

Vicodin
    Dosage: 5/500 prn

Ambien
    Dosage: 10 mg, 1x/day
    Administration route: Oral

Blinded Placebo
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Blinded NO Subject Drug
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Zestoretic
    Dosage: 20/12.5 daily

Lyrica
    Dosage: 75 mg, 1x/day

Fluticasone Furoate
    Dosage: 2 sprays daily

Abilify
    Dosage: 15 mg, 2x/day

Vivelle
    Dosage: 0.1 mg, unk

Loratadine
    Dosage: 10 mg, 1x/day

Robaxin
    Dosage: 750 mg, 3x/day
    Administration route: Oral



Possible Vivelle side effects in female

Reported by a physician from United States on 2011-12-19

Patient: female, weighing 89.4 kg (196.7 pounds)

Reactions: Dysarthria, Polymedication, Mental Status Changes, Condition Aggravated, Hypertension, Hypokalaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Abilify
    Dosage: 15 mg, 2x/day

Blinded Placebo
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Fluticasone Propionate
    Dosage: 2 sprays daily

Vicodin
    Dosage: 5/500 prn

Ambien
    Dosage: 10 mg, 1x/day
    Administration route: Oral

Blinded Desvenlafaxine Succinate Monohydrate
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Lyrica
    Dosage: 75 mg, 1x/day

Vivelle
    Dosage: 0.1 mg, unk

Blinded Desvenlafaxine Succinate Monohydrate
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Blinded NO Subject Drug
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Robaxin
    Dosage: 750 mg, 3x/day
    Administration route: Oral

Blinded Placebo
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Ibuprofen
    Dosage: 800 mg, 3x/day

Clonazepam
    Dosage: 1 mg, 2x/day

Loratadine
    Dosage: 10 mg, 1x/day

Zestoretic
    Dosage: 20/12.5 daily

Blinded NO Subject Drug
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Lexapro
    Dosage: 20 mg, 1x/day



Possible Vivelle side effects in female

Reported by a physician from United States on 2011-12-16

Patient: female, weighing 89.4 kg (196.7 pounds)

Reactions: Dysarthria, Polymedication, Condition Aggravated, Mental Status Changes, Hypertension, Hypokalaemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Lexapro
    Dosage: 20 mg, 1x/day

Vivelle
    Dosage: 0.1 mg, unk

Blinded NO Subject Drug
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Blinded Desvenlafaxine Succinate Monohydrate
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Blinded NO Subject Drug
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Blinded Placebo
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Loratadine
    Dosage: 10 mg, 1x/day

Robaxin
    Dosage: unknown

Abilify
    Dosage: 15 mg, 2x/day

Ibuprofen
    Dosage: 800 mg, 3x/day

Clonazepam
    Dosage: 1 mg, 2x/day

Fluticasone
    Dosage: 2 sprays daily

Zestoretic
    Dosage: 20/12.5 daily

Ambien
    Dosage: 10 mg, 1x/day
    Administration route: Oral

Lyrica
    Dosage: 75 mg, 1x/day

Robaxin
    Dosage: 750 mg, 3x/day
    Administration route: Oral

Blinded Placebo
    Dosage: blinded therapy daily
    Administration route: Oral
    Indication: Menopausal Symptoms
    Start date: 2008-09-09
    End date: 2008-11-22

Blinded Desvenlafaxine Succinate Monohydrate
    Dosage: blinded therapy daily
    Administration route: Oral
    Start date: 2008-11-29
    End date: 2008-12-24

Vicodin
    Dosage: 5/500 prn

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017